REBISTART: Adherence of Patients with Multiple Sclerosis to Treatment with Subcutaneous Interferon Beta in the Context of a Patient Support Program.
Adherence
Interferon beta-1a sc
Multiple sclerosis
Patient support program
Subcutaneous injection
Journal
Neurology and therapy
ISSN: 2193-8253
Titre abrégé: Neurol Ther
Pays: New Zealand
ID NLM: 101637818
Informations de publication
Date de publication:
26 Mar 2024
26 Mar 2024
Historique:
received:
12
09
2023
accepted:
16
02
2024
medline:
26
3
2024
pubmed:
26
3
2024
entrez:
26
3
2024
Statut:
aheadofprint
Résumé
Treatment adherence is a critical success factor in the disease-modifying therapy (DMT) of multiple sclerosis (MS). The REBISTART study prospectively evaluated adherence in patients using components of a patient support program (PSP). The 12-month non-interventional multicenter study examined the real-world adherence to subcutaneously (sc) injected interferon beta-1a (Rebif Of 333 patients, 70.9% used the nursing service as the core component of the PSP. Self-assessed VAS-based adherence was stable over time at 94.0-96.3%. Similarly, MMAS score (maximum 4) was 3.8-3.9 at all visits, also reflecting high self-assessed adherence. In 269 patients using the RebiSmart We suggest that subgroups that may specifically benefit from PSP include patients who live alone, use multiple comedications, and are affected by cognitive impairment, depression, and/or fatigue. Further studies should investigate the potential usefulness of PSPs in these populations. Very high adherence rates independent of the PSP nursing service over 1 year of treatment indicate that IFN beta-1a sc is an easy-to-use and well-tolerated disease-modifying drug. Vfa.de: No. 892. https://www.vfa.de/de/arzneimittel-forschung/datenbanken-zu-arzneimitteln/nisdb/nis-details/_892 .
Identifiants
pubmed: 38530606
doi: 10.1007/s40120-024-00593-x
pii: 10.1007/s40120-024-00593-x
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.
doi: 10.1056/NEJMra050100
pubmed: 16079372
Sabaté E. Adherence to long-term therapies. Evidence for action. World Health Organization; 2003. http://apps.who.int/medicinedocs/pdf/s4883e/s4883e.pdf .
Kern S, Reichmann H, Ziemssen T. Therapieadhärenz in der neurologischen Praxis. Beispiel: Multiple Sklerose [Adherence to neurologic treatment. Lessons from multiple sclerosis]. Nervenarzt. 2008;79:877–90.
doi: 10.1007/s00115-008-2419-0
pubmed: 18335191
Erbay Ö, Usta Yeşilbalkan Ö, Yüceyar N. Factors affecting the adherence to disease-modifying therapy in patients with multiple sclerosis. J Neurosci Nurs. 2018;50:291–7.
doi: 10.1097/JNN.0000000000000395
pubmed: 30138155
Higuera L, Carlin CS, Anderson S. Adherence to disease-modifying therapies for multiple sclerosis. J Manag Care Spec Pharm. 2016;22:1394–401.
pubmed: 27882830
Moghadasi AN, Pourmand S, Sharifian M, et al. Behavioral neurology of multiple sclerosis and autoimmune encephalopathies. Neurol Clin. 2016;34:17–31.
doi: 10.1016/j.ncl.2015.08.002
pubmed: 26613993
Rice DR, Kaplan TB, Hotan GC, et al. Electronic pill bottles to monitor and promote medication adherence for people with multiple sclerosis: a randomized, virtual clinical trial. J Neurol Sci. 2021;428:117612.
doi: 10.1016/j.jns.2021.117612
pubmed: 34392138
Nicholas JA, Edwards NC, Edwards RA, Dellarole A, Grosso M, Phillips AL. Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis. BMC Neurol. 2020;20:281.
doi: 10.1186/s12883-020-01830-0
pubmed: 32664928
pmcid: 7371467
Rieckmann P, Ziemssen T, Penner IK, et al. Adherence to subcutaneous interferon beta-1a in multiple sclerosis patients receiving periodic feedback on drug use by discussion of readouts of their RebiSmart
doi: 10.1007/s12325-022-02100-w
pubmed: 35428903
pmcid: 9122862
European Medicines Agency. Rebif
Moccia M, Palladino R, Russo C, et al. How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis. Expert Opin Drug Deliv. 2015;12:1829–35.
doi: 10.1517/17425247.2015.1078789
pubmed: 26371561
Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292–302.
doi: 10.1002/ana.22366
pubmed: 21387374
pmcid: 3084507
IQVIA Longitudinal Prescription Data (LRx), 09/2021; Merck Serono, data on file.
Rieckmann P, Schwab M, Pöhlau D, et al. Adherence to subcutaneous IFN β-1a in multiple sclerosis: final analysis of the non-interventional study READOUTsmart using the dosing log and readout function of RebiSmart
doi: 10.1007/s12325-018-0839-1
pubmed: 30488338
Vališ M, Šarláková J, Halúsková S, et al. An observational study demonstrating the adherence and ease of use of the injector device, RebiSmart
doi: 10.1080/17425247.2020.1742694
pubmed: 32315204
Sauri-Suárez S, Quiñones-Aguilar S, Contreras-Marín A, et al. Adherence to self-administering interferon-β1a using RebiSmart
doi: 10.1371/journal.pone.0230959
pubmed: 32310950
pmcid: 7170219
Deftereos SN, Koutlas E, Koutsouraki E, et al. Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart
doi: 10.1186/s12883-018-1179-0
pubmed: 30400884
pmcid: 6218994
Pedersen ED, Stenager E, Vadgaard JL, et al. Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study). Patient Prefer Adher. 2018;12:569–75.
doi: 10.2147/PPA.S154417
Zecca C, Disanto G, Mühl S, et al. Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart
doi: 10.1186/s12883-017-0952-9
pubmed: 28870152
pmcid: 5584024
Ghezzi A, Bianchi A, Baroncini D, et al. A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™-the FUTURE study. Neurol Sci. 2017;38:1999–2005.
doi: 10.1007/s10072-017-3091-6
pubmed: 28831635
Krol M, de Voer G, Osowski U. Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart
doi: 10.2147/PPA.S130985
Fernández O, Arroyo R, Martínez-Yélamos S, et al. Long-term adherence to IFN beta-1a treatment when using RebiSmart
doi: 10.1371/journal.pone.0160313
pubmed: 27526201
pmcid: 4985132
Paolicelli D, Cocco E, Di Lecce V, et al. Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. Expert Opin Drug Deliv. 2016;13:799–805.
doi: 10.1517/17425247.2016.1158161
pubmed: 26922837
Lugaresi A, De Robertis F, Clerico M, et al. Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study. Expert Opin Drug Deliv. 2016;13:931–5.
doi: 10.1517/17425247.2016.1148029
pubmed: 26909646
Bayas A, Ouallet JC, Kallmann B, et al. Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart
doi: 10.1517/17425247.2015.1057567
pubmed: 26098143
Willis H, Webster J, Larkin AM, et al. An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart
doi: 10.2147/PPA.S54986
Lugaresi A, Florio C, Brescia-Morra V, et al. Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. BMC Neurol. 2012;12:7.
doi: 10.1186/1471-2377-12-7
pubmed: 22390218
pmcid: 3368780
D’Arcy C, Thomas D, Stoneman D, et al. Patient assessment of an electronic device for subcutaneous self-injection of interferon β-1a for multiple sclerosis: an observational study in the UK and Ireland. Patient Prefer Adher. 2012;6:55–61.
doi: 10.2147/PPA.S26250
Thompson MT, Virginia D, Nick B, et al. Adherence and discontinuation rates in patients on Tecfidera™ (dimethyl fumarate): long-term Canadian experience from the Biogen ONE™ support program. Mult Scler Relat Disord. 2022;67:104080.
doi: 10.1016/j.msard.2022.104080
pubmed: 35973386
Vermersch P, Suchet L, Colamarino R, Laurendeau C, Detournay B. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014–2017. Mult Scler Relat Disord. 2020;46:10252.
doi: 10.1016/j.msard.2020.102521
Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18:69–77.
doi: 10.1111/j.1468-1331.2010.03110.x
pubmed: 20561039
Menzin J, Caon C, Nichols C, White LA, Friedman M, Pill MW. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm. 2013;19(1 Suppl A):S24-40.
pubmed: 23383731
Moccia M, Loperto I, Lanzillo R, et al. Persistence, adherence, healthcare resource utilisation and costs for interferon beta in multiple sclerosis: a population-based study in the Campania region (southern Italy). BMC Health Serv Res. 2020;20:797.
doi: 10.1186/s12913-020-05664-x
pubmed: 32847587
pmcid: 7448448
Tan H, Cai Q, Agarwal S, et al. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther. 2011;28:51–61.
doi: 10.1007/s12325-010-0093-7
pubmed: 21153000
Roche J, McCarry Y, Mellors K. Enhanced patient support services improve patient persistence with multiple sclerosis treatment. Patient Prefer Adher. 2014;8:805–11.
doi: 10.2147/PPA.S59496